Basel, 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors First new medicine in nearly 20 years to treat people with haemophilia A with inhibitors Hemlibra substantially reduced bleeds in adults and children Only medicine that can be self-administered once weekly by injection under the skin (subcutaneously) Roche (SIX: RO, ROG;... Read more
– Kit expands multiplexing options, allowing more biomarkers to be investigated on a single tissue slide – Multiplexed assays for simultaneously detecting several biomarkers in a single sample address growing need to obtain more information from limited tissue samples TUCSON, Arizona, Nov. 16, 2017 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the... Read more
Basel, 10 November 2017 Roche’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS will be an important treatment option for people with active relapsing forms of multiple sclerosis (RMS) showing superior efficacy on three major markers of disease activity and disability progression compared... Read more
Basel, 07 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced... Read more
Basel, 07 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food... Read more
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
Basel, 31 October 2017 New data suggest Roche’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease Roche presents etrolizumab data in Crohn’s disease and ulcerative colitis at UEGW Data suggest etrolizumab leads to endoscopic improvement associated with early symptomatic remission in Crohn’s disease... Read more
Basel, 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS) Data demonstrates first method to automatically detect and characterise... Read more
26 October 2017 FDA accepts Roche’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) in combination with chemotherapy (carboplatin... Read more